Editor: What To Know
- He is a highly respected leader in the global M&A community and I am confident he will make significant contributions to our ongoing success as we execute our growth and value creation strategy.
- Reali said, “Chris is coming on board at an exciting time at Bioventus as we seek to accelerate growth and build scale and depth in our offerings through both organic and inorganic investment.
- He will be responsible for developing an inorganic growth strategy for the company and executing deals that will drive long-term value and further the company's mission of helping patients regain active lifestyles.
Chris Yamamoto has been appointed Bioventus Senior VP of Business Development and Strategy.
Chris Yamamoto brings nearly 20 years of experience in mergers & acquisitions and business development. He will be responsible for developing an inorganic growth strategy for the company and executing deals that will drive long-term value and further the company’s mission of helping patients regain active lifestyles. Yamamoto will report to Bioventus CEO Ken Reali and will join the company’s executive leadership team.
Reali said, “Chris is coming on board at an exciting time at Bioventus as we seek to accelerate growth and build scale and depth in our offerings through both organic and inorganic investment.” He concluded, “We are pleased to welcome Chris to the team. He is a highly respected leader in the global M&A community and I am confident he will make significant contributions to our ongoing success as we execute our growth and value creation strategy.”
Yamamoto joins Bioventus from Becton Dickinson and Company where he spent the last six years, most recently as Vice President and Managing Director of Corporate Development. Prior to Becton Dickinson, Yamamoto was a Vice President with The Blackstone Group. He also worked at Fox Paine, Thoma Cressey, UBS Investment Bank and other institutions. Yamamoto received a Bachelor of Arts in Economics cum laude from Williams College.
